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http://dx.doi.org/10.1016/j.jmii.2013Leclercia adecarboxylata, a ubiquitous Gram-negative bacillus, is generally viewed as an
opportunistic pathogen because it is rarely cultured from clinical samples. Although rare,
bacteremia due to L. adecarboxylata tends to occur in immunocompromised hosts and patients
with systemic comorbidities. Only one case of bacteremia due to L. adecarboxylata has been
reported in a previously healthy patient. We describe a male patient with an active peptic ul-
cer who developed L. adecarboxylata bacteremia after a long-term use of nonsteroidal anti-
inflammatory drugs. The abdomen is believed to have been the most probable portal of entry.
After appropriate medical management, the patient recovered without sequela.
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confirmation of the accuracy of L. adecarboxylata identi-Leclercia adecarboxylata, a motile, aerobic, Gram-
negative bacillus, first described by Leclerc in 1962,1 is
ubiquitously distributed in nature and has been isolated
from food, water, and other environmental sources.2 L.
adecarboxylata is generally viewed as a bystander because
of its rare frequency of isolation from clinical samples. L.
adecarboxylata bacteremia predominantly occurs in pa-
tients with some degree of immunosuppression3e6 and in
those with end-stage renal disease.7,8 However, bacteremia
due to L. adecarboxylata has never been reported in pa-
tients with peptic ulcers. Herein we report a case of L.
adecarboxylata bacteremia in a patient with a duodenal
ulcer after overuse of nonsteroidal anti-inflammatory drugs
(NSAIDs) and present a review of relevant literature
regarding bacteremia due to L. adecarboxylata in healthy
patients without a history of trauma.
Case report
A 66-year-old man with a history of hemorrhage in the
upper gastrointestinal tract was hospitalized in April 2012
because of epigastralgia, tarry-stool passage, and
abdominal fullness for 4 days. The patient did not present
with symptoms or signs of sepsis initially, but mentioned
that he had been taking indomethacin as well as other
NSAIDs for approximately 6 months to relieve joint pain.
No immunosuppressive or antimicrobial agents had been
administered prior to his admission, and no diarrhea
developed prior to the occurrence of tarry-stool passage.
Panendoscopy revealed a duodenal ulcer (Forrest classifi-
cation 1a, sprouting hemorrhage) with exposed vessel in
the postbulbar duodenum. Epinephrine was administered
in combination with heater probe thermal coagulation
treatment. The patient also received a transfusion of
packed red blood cells and was administered a parenteral
proton-pump inhibitor (omeprazole 40 mg, every 12
hours). Hemogram obtained on Day 1 of hospitalization
revealed eosinophilia (1160/mm3). On Day 4 of hospitali-
zation, the patient presented with chills and spiking fever.
No intravenous administration of fluids or drugs was given
at that time. A detailed physical examination did not
reveal any infectious focus. Findings on chest and
abdominal X-rays were normal. Laboratory findings
revealed a reduced white blood cell count (1910/mm3),
normal serum creatinine concentration (1.1 mg/dL), and
mildly elevated C-reactive protein concentration
(2.78 mg/dL). Based on the laboratory findings, the pa-
tient was administered cefmetazole at an intravenous
dose of 1 g every 8 hours.
Two blood culture sets from this patient grew L. ade-
carboxylata. The biochemical profile for L. adecarboxylata
included the following: (1) negative reactions for citrate,
lysine decarboxylase, ornithine decarboxylase, arginine
dihydrolase, DNase, and hydrogen sulfide, and (2) positive
reactions for esculin hydrolysis, indole production,
VogeseProskauer test, and malonate assimilation. In addi-
tion, manual tube tests for sugar fermentation included
positive reactions for adonitol, D-melibiose, sucrose,
D-arabitol, raffinose, L-rhammnose, and lactose, butnegative reactions for myo-inositol and D-sorbitol. For
fication, we used two automated systems including the
Microscan (Spectris Company, West Sacramento, CA, USA)
and the BD crystal (Becton Dickinson & Company, Sparks,
MD, USA). The bio numbers of this strain were 67310230 and
5764427552, respectively, with the probability of L. ade-
carboxylata being 99.0% and 99.4%. In accordance with the
guidelines of the Clinical and Laboratory Standards Institute
2012 (Escherichia coli ATCC 25922 and E. coli ATCC 35218 as
quality control strains),9 the L. adecarboxylata isolate was
susceptible to all antimicrobial agents tested, including
ampicillin, ampicillinesulbactam, cefazolin, cefmetazole,
cefotaxime, ceftazidime, cefepime, piperacillin/tazo-
bactam, ertapenem, gentamicin, amikacin, and ciproflox-
acin. After cefmetazole was administered, rapid
defervescence and gradual recovery of the patient’s
leukocyte count were noted. The immunologic survey
resulted in the following findings: the ratio of CD4 to CD8
leukocyte count (on Day 6 of hospitalization) was grossly
normal (2.05); there was no evidence of hyperglycemia
(i.e., serum glucose concentration  140 mg/dL); and the
serological results of human immunodeficiency virus and
important autoimmune antibodies were all negative. How-
ever, persistent eosinophilia (958/mm3, with a total
leukocyte count of 3990/mm3, on Day 6 of hospitalization)
drew our attention. The sole abnormal finding on his
abdominal sonographic investigation was fatty liver.
Further investigations were performed to determine the
cause of persistent eosinophilia. Neither parasites nor ova
were detected in stool samples. Although the levels of
serum lactic dehydrogenase (164 U/L; normal range,
100e190 U/L) and serum gamma-GT (26 U/L; normal range,
0e48 U/L) were normal, IgE level (771 mg/dL; normal level,
<100 mg/dL) was elevated markedly. We suspected that
the eosinophilia was drug related. The proton-pump inhib-
itor agent was, therefore, changed to an H2 antagonist
(famotidine) and cephalosporin was switched to oral cip-
rofloxacin 500 mg twice a day as the maintenance antibiotic
agent. Follow-up hemogram on Day 16 of hospitalization
showed resolution of eosinophilia, and the patient recov-
ered without sequela.Discussion
Our patient did not show evidence of any intra-abdominal
problems with the exception of a duodenal ulcer. However,
he had habitually abused NSAIDs prior to the development
of bacteremia due to L. adecarboxylata. The majority
(>67%) of cases of L. adecarboxylata bacteremia occur in
immunosuppressed patients.10 Based on a review of the
literature, only one immunocompetent patient without a
history of chronic systemic comorbidities or recent trauma
has been reported to have developed bacteremia due to L.
adecarboxylata.11 Studies have shown that overuse of
NSAIDs can result in immunosuppression12; however, it is
not clear whether chronic NSAID usage in our patient
resulted in a suppressed immune system.
It is noteworthy that the eosinophil count in our patient
was less than 1500/mm3 (the threshold for hypereosinophilic
syndrome, the definition of which also includes its
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damage).13 Besides, his clinical condition was clearly not
compatible with hypereosinophilic syndrome or Churge
Strauss syndrome (asthma, pulmonary infiltrates, and
dermatologic manifestation of necrotizing vasculitis,
which were primarily relieved by glucocorticoids).14
Furthermore, his normal serum lactic dehydrogenase level
and end-organ function, and lack of evidence of parasitic
infestation suggest that the eosinophilia was possibly caused
by drugs. In addition, the subsidence of eosinophilia after our
patient’s medication was adjusted indicates that the eosin-
ophilia was due to medication prescribed during
hospitalization.
To the best of our knowledge, no evidence exists for an
association between L. adecarboxylata bacteremia and
peptic ulcers. Although peptic ulcers have not been re-
ported as an entry portal into the bloodstream for patho-
genic organisms, we still suspect that the bacteremic strain
in this patient originated in the abdomen. L. adecarbox-
ylata, which is generally considered to be a benign
bystander in humans, may have a propensity to invade the
bloodstream of patients with specific abdominal stress,
such as the duodenal ulcer.
In contrast to the drug-resistant L. adecarboxylata
bacteremic isolates occasionally cultured from immuno-
compromised patients,5,15 the isolate obtained from our
patient was susceptible to all tested antimicrobial agents.
Similar findings have been reported earlier,2,11 suggesting
that most cases of L. adecarboxylata are relatively easy to
treat.
In conclusion, we have presented a patient with peptic
ulcer and a long-term history of NSAID usage who devel-
oped bacteremia due to L. adecarboxylata. Although this
pathogen is usually susceptible to most antibiotics, infec-
tion with L. adecarboxylata can result in bacteremia in
immunocompetent hosts with some degree of abdominal
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